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Objectives This study sought to evaluate the safety of percutaneous direct left ventricular access
for interventional procedures.
Background Experience with percutaneous access of the left ventricle (LV) for interventional proce-
dures has been limited and associated with a high percentage of major complications. We report
our clinical experience with percutaneous direct LV access for interventional procedures.
Methods Between March 2008 and December 2010, there were 32 percutaneous transapical punc-
tures in 28 consecutive patients (16 males, mean age 68.2  10.8 years). The delivery sheath sizes
ranged from 5- to 12-F.
Results All transapical punctures were successfully performed, and safe closure of the access sites
was achieved. Total procedural time was 153.6  49.4 min for procedures converted from conven-
tional approaches to a transapical approach, 129.5  29.6 min for the transapical approach with
rans-septal rail support, and 109.3  41.4 min for the planned transapical approach. Fluoroscopy
ime was 61.3  26.1 min, 29.7  20.8 min, and 27.4  21.4 min, respectively. Fluoroscopy time for
closure of mitral paravalvular leaks was reduced by 35%, from 42.6  29.9 min to 27.4  15.6 min.
Complications were observed in 2 patients (7.1%).
Conclusions With meticulous planning, transapical puncture is safe. The transapical access provides
a more direct approach to the LV targets for intervention and leads to a signiﬁcant decrease in the
procedural and ﬂuoroscopy times. Device closure of the direct LV access site is a reliable and safe
method of hemostasis. Placement of a closure device should be considered if sheaths larger than
5-F are used. Although we used this technique only for paravalvular leak and LV pseudoaneurysm
closure, it may have application for other percutaneous structural heart interventions. (J Am Coll
Cardiol Intv 2011;4:868–74) © 2011 by the American College of Cardiology Foundation
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from Philips Healthcare and is a research grant recipient from GE Healthcare. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.Manuscript received March 17, 2011; revised manuscript received May 24, 2011, accepted May 31, 2011.
b
t
v
c
i
h
m
i
i
C
t
i
p
w
(
e
s
w
p
a
r
c
c
u
s
a
l
i
i
t
i
p
c
p
c
fl
C
fl
w
n
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1 Jelnin et al.
A U G U S T 2 0 1 1 : 8 6 8 – 7 4 Percutaneous Direct Left Ventricular Access
869For more than half a century, transapical left ventricular (LV)
access has been used for diagnostics and hemodynamic assess-
ment (1). Recently, direct LV access has also been used for
interventional procedures (2–6). The largest experience has
een gained from the direct surgical exposure of the LV
hrough a mini-thoracotomy, mostly for transcatheter aortic
alve implantation as well as for other interventions, although
information about the safety of this approach is scarce.
See page 875
The experience with percutaneous access of the LV for
interventional procedures has also been limited and associ-
ated with a high percentage of major complications (3–5).
In this paper, we report our single-center clinical experience
on percutaneous direct LV access and closure of the access
site for different transcatheter interventions.
Methods
Patient population. Between March 2008 and December
2010, 32 procedures with direct LV access were performed in
28 patients undergoing percutaneous closure of mitral paraval-
vular leak or LV pseudoaneurysm repair. Sixteen patients
(57%) were males, and the mean age was 68.2  10.8 years.
Twenty-six patients underwent paravalvular leak repair, and 2
patients underwent repair of post-myocardial infarction LV
pseudoaneurysm.
Fourteen patients had 1 prosthetic valve (2 mechanical, 12
biological), and 12 patients had 2 prosthetic valves (9 with both
mechanical, 2 with both biological, and 1 with a mechanical
aortic valve and a biological mitral valve). Patients exhibited a
multitude of comorbidities: all patients had congestive heart
failure, 18 (64%) had systemic hypertension, 12 (43%) had
pulmonary hypertension, 11 (40%) experienced atrial fibrilla-
tion, 6 (21%) had a permanent pacemaker, 13 (46%) had
extensive coronary artery disease, and 8 (31%) had previous
coronary artery bypass graft surgery. All patients were in New
York Heart Association functional class II to IV.
All procedures were performed in the dedicated structural
heart catheterization laboratory under general anesthesia.
Patients were advised of the procedural risks and options as
well as the off-label use of all closure devices. Signed
informed consent was obtained from all patients before the
procedure. This retrospective study was approved by Lenox
Hill Hospital’s institutional review board.
Imaging echocardiography. All patients had 2-dimensional
echocardiographic evaluation before each procedure. Two-
dimensional and real-time 3-dimensional (3D) transesoph-
ageal echocardiogram (TEE) was used throughout each
procedure. An Philips iE-33 with the 7-T to 2-T 3D
TEE probe (Philips Healthcare, Andover, Massachusetts)
was used. Three-dimensional modalities included live real-time, real-time 3D zoom, and full-volume acquisition with
and without color flow imaging.
Images were obtained and recorded during each stage of
the procedure. The operator used the information thus
obtained to guide the catheters and devices throughout the
procedure (Fig. 1).
At the end of the procedure, careful echocardiographic
evaluation was performed to exclude complications such as
pericardial effusion, intracardiac clot, and so forth.
Computed tomography angiography. All patients underwent
ardiac computed tomographic angiography (CTA) (256-slice
CT scanner, Philips Healthcare, Cleveland, Ohio) using
elical scan mode with retrospective electrocardiogram-gated
ultiphase reconstruction (16 phases with 6.25% interval
ncrements from RR interval) before the procedure. An Aquar-
us workstation (V-3.7.0.14, TeraRecon Inc., San Mateo,
alifornia) was used for 3D/4D volume rendering reconstruc-
ion for selecting the optimal entry point from the chest wall
nto the LV cavity. This included location of the cardiac apex,
apillary muscles, and coronary arteries in relation to the chest
all, and the extension of the lung tissue over the LV cavity
Figs. 2 and 3). After the target
ntry point was selected and mea-
urements obtained, an ink mark
as placed on the skin of the
atient.
During the procedure, pre-
cquired CTA (4D volume
endering) was displayed in the
atheterization laboratory adja-
ent to the fluoroscopy image,
sing a grayscale preset that
imulates the fluoroscopy im-
ge. The reconstructed images were rotated and angu-
ated according to the movement of the fluoroscopy
mage intensifier, allowing the CTA and the fluoroscopy
mages to be congruent throughout the procedure. This
echnique was used for transapical access as well as for
ntervening on the targeted defects.
More recently, we have also instituted the use of a
rototype software “HeartNavigator” (Philips Health-
are, Best, the Netherlands) that allows overlay of a
re-acquired CTA image with live fluoroscopy. After
oregistration, the overlaid 3D CTA images track the
uoroscopy image. Multiple target points marked on the
TA image can therefore be accurately projected on the live
uoroscopy indicating the entry point at the skin level, as
ell as into the myocardial surface, that can guide the
eedle access (Fig. 4).
Technique of direct LV access. All procedures were per-
formed under general anesthesia. The puncture site was
marked with ink on the patient’s skin, according to mea-
surements obtained from the CTA analysis. If the anterior
Abbreviations
and Acronyms
3D  3-dimensional
CTA  computed
tomographic angiography
LA  left atrium
LV  left
ventricle/ventricular
TEE  transesophageal
echocardiographyborder of the left lung overlapped the desired puncture site
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870on the LV (Fig. 2B) the anesthesiologist was asked to
deflate the left lung to minimize exposure of the lung tissue.
A selective coronary angiogram was also used for patients in
whom the CTA revealed proximity of the coronary arteries to
the puncture site. The transapical puncture was accomplished
by accessing the LV cavity percutaneously with a 21-gauge
micropuncture needle (Cook Medical, Bloomington, Indiana).
The procedures were guided by live fluoroscopy and
monitored with TEE. During the puncture, contrast was
injected through the needle to monitor the entry into the
LV cavity. After cannulating the LV, a 0.018-inch guide-
wire was advanced through the needle, and the needle was
exchanged for a 5-F radial sheath (Cook Medical). Appro-
Figure 1. Intraprocedure Real-Time, Live 3D TEE Images, Deep Transgastri
(A) Entrance of the puncture needle (white arrow) into the LV cavity from the
Occluder device (AGA Medical Corporation) (black arrow). 3D  3-dimensiona
Figure 2. Volume-Rendered CTA Demonstrates Variation of the “Safe Punc
(A) Patient with good exposure of the LV apex with a large puncture window
and close proximity of the coronary artery. CTA  computed tomographic angiograpriate delivery sheaths were then introduced according to
the interventional needs and ranged from 5- to 12-F.
Technique for closure of the direct LV access. In 4 patients
ith a transapical access sheath of 5-F, the access site was not
losed. As previously reported, the closure of a transapical
ccess site in 1 patient was performed using 2 0.052-inch
ianturco Coils (Cook Medical) (7). In 1 patient, the LV
ccess was closed using a 6-mm Amplatzer Muscular VSD
ccluder (AGA Medical Corporation, Plymouth, Minne-
ota). All other transapical accesses were closed using a
-mm to 4-mm Amplatzer Duct Occluder (AGA Medical
orporation). The implantation of the closure device is
erformed under real-time fluoroscopy guidance. The de-
gitudinal Views
t wall. (B) Closure of the transapical access site with Amplatzer Duct
left ventricle; TEE  transesophageal.
indow” Among Different Patients
w shaded). (B) Patient with small puncture window because of lung overlapc Lon
chesture W
(yello
phy; LAD  left anterior descending; LV  left ventricle.
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871vice is delivered through the delivery sheath, and after the
opening of the distal disk, the device is pulled back until
resistance is felt and the flat disk conforms to the endocar-
dial surface. The proper position of the device can be
confirmed by fluoroscopy when visual elongation of the
body of the device during each systolic contraction is noted.
Before device release, echocardiographic confirmation of the
device placement is obtained, and contrast injected through
the delivery sheath confirms the pericardial position of the
sheath. After device release, Surgiflo (Ethicon, Somerville,
New Jersey) is injected through the delivery sheath, to fill
the track from the epicardium to the skin.
Results
All transapical accesses were successful, with no complica-
tions associated with the percutaneous LV puncture. In all
4 patients with 5-F access sheaths, no device closure of the
access site was performed, and there were no complications
observed in this group. In all other patients, the access site
was successfully closed. There was 1 instance of a small
pericardial effusion documented by echocardiography that
required no further intervention. There was 1 procedure-
related death in a patient with suprasystemic pulmonary
Figure 3. Planning a Safe Transapical Puncture Using Cardiac CTA Guidan
(A) standard coronal, (B) lateral, and (C) axial views with 3-dimensional (3D
allows the measurement of distances in 3 dimensions from the skin to epic
[St. Jude Medical, St. Paul, Minnesota] with paravalvular leak) inside the LV
anterior-posterior view (D) and 60° left anterior oblique view (H) demonstrati
apex, lung tissue, and identiﬁable anatomical landmarks such as the sternu
tool and “slab” view applied. Abbreviations as in Figure 2.hypertension who developed pulseless electrical activity ((electromechanical dissociation) after transapical paravalvu-
lar leak closure and transapical puncture closure. Two-
dimensional echocardiography and emergency thoracotomy
did not show any pericardial effusion.
Two patients had repeat transapical access for closure of
additional paravalvular leaks. In an additional 2 patients, a
double transapical access, for simultaneous deployment and
release of 2 closure devices for a crescent-shaped paravalvu-
lar leak, was performed (Fig. 5).
The patients that underwent paravalvular leak closure
procedures were divided into 3 groups. Group A included 6
patients in whom the primary intended retrograde (arterial)
and/or trans-septal (venous) approaches failed and proce-
dures were converted to the transapical approach. Group B
included 10 patients in whom a direct transapical approach
combined with trans-septal access to create a venous–LV apical
rail was initially planned. Group C included 10 patients in
whom a solo transapical approach was used. Average fluoros-
copy time was 61.3 26.1 min for group A, 29.7 20.8 min
for group B, and 27.4 21.4 min for group C. Total procedural
time was 153.6  49.4 min for group A, 129.5  29.6 min for
group B, and 109.3  41.4 min for group C (Fig. 6).
All patients were clinically followed up to 33 months
et tool overlaid on the image. The red circle with measuring scales
l surface as well as to the target lesion (St. Jude prosthetic mitral valve
w arrow). (D and H) 3D volume-rendered reconstruction image in
puncture site on the skin (blue arrow) and its relationship to the cardiac
, F, and G) standard coronal, lateral, and axial views with 3D measuringce
) targ
ardia
(yello
ng the
m. (Eaverage 13.8  9.7 months, range 1 to 33 months)
arro
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872post-procedure. There were no long-term complications
observed resulting from the transapical puncture or puncture
site closure during this period.
Discussion
Since the 1950s, percutaneous transapical puncture has
been used mostly for diagnostic purposes. Braunwald (8)
reported an overall cooperative experience in 1968 of LV
Figure 4. Planning and Execution of the Transapical Puncture Using HeartN
(A) Marking of optimal transapical puncture site using a prototype software p
placed on maximum-intensity projection views at the skin surface (landmark 3
mark 1). (B) Superimposition of landmarks on live ﬂuoroscopy. Catheter (whitepuncture in 260 patients, with only 8 patients (3.1%)suffering major complications. Havranek and Sherry (9)
reported overall procedure-related mortality of 0.5%,
cardiac tamponade in 1.4%, and pleural complications in
2.7% in a review of 1,100 procedures in the literature.
However, these results for diagnostic LV punctures were
all from puncture needles and cannot be applied, there-
fore, to LV access for interventional procedures. A recent
series by Pitta et al. (5) showed that the overall compli-
cation rate for direct LV access was 37.5%; however, the
tor Software
(Philips Healthcare, Best, the Netherlands). “Landmarks” (yellow dots) are
y point to the LV chamber (landmark 2), and mitral paravalvular leak (land-
w) introduced in the LV aiming yellow landmarks 2 and 3.aviga
ackage
), entrcomplication rate for those undergoing interventional
r (AG
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873procedures was 62% (8 of 13 patients). The most com-
mon complication was a hemothorax that they suggested
could be caused by bleeding from the LV puncture site or
laceration of the coronary, pleural, or intercostal vessels
during the access.
In our study, complications were observed in 2 patients
(7.1%): 1 instance of small pericardial effusion and 1 electro-
mechanical dissociation that resulted in death in a patient with
suprasystemic pulmonary hypertension. Cause of death re-
mains unknown; however, electromechanical dissociation in
Figure 5. Closing of the Transapical Puncture Site After the Double Punctu
(A) Double transapical puncture. (B) Deployment of 2 Amplatzer Duct Occlude
Figure 6. Average Procedural and Fluoroscopy Time for Mitral Paravalvular
Group A: procedures converted from failed primary intended retrograde (arter
cedures with direct transapical combined with trans-septal access to create a venoupatients with severe pulmonary hypertension has been previ-
ously described (10,11).
In our experience, the integration of previously acquired
CTA images has been very useful for the planning and
execution of direct needle entry into the LV cavity in an
accurate and safe manner. In some patients, the transgastric
TEE views may allow visualization of the anterior LV wall
to guide the needle access. However, usefulness of this
imaging modality is somewhat limited because of poor
exposure of the LV apex. Therefore, a careful selection of
A Medical Corporation) devices closing a double puncture (white arrows).
Closure Within the Transapical Group
d/or trans-septal (venous) approaches to transapical approach. Group B: pro-reLeak
ial) an
s–left ventricular apical rail. Group C: a solo transapical approach.
4
o
t
p
p
c
i
p
p
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 8 6 8 – 7 4
Jelnin et al.
Percutaneous Direct Left Ventricular Access
874the access site based on multi-imaging information is
recommended to minimize complications associated with
“blind puncture.”
On the basis of our results, it seems prudent to recommend
closure of the LV access site, especially if the sheaths used are
6-F or larger. We believe that the main contributor to our low
complication rate for transapical cardiac interventions com-
pared with previous reports (3–5) is due to the closure of the
puncture site. Our method of closure has proven to be effective
and reliable for sheath sizes up to 12-F.
Although the longest follow-up is 36 months, a longer
follow-up period is necessary before a definitive conclusion
about the safety of using these devices for sealing the LV
access can be reached.
In our series of paravalvular leak closure (12), the
transapical approach resulted in a 35% decrease in the
fluoroscopy time (27.4  15.6 min compared with a total
2.6 29.9 min) when compared with conventional arterial
r venous access (Fig. 7). Furthermore, analysis within the
ransapical group showed that the planned transapical ap-
roach (group C) resulted in the shortest fluoroscopy and
rocedural times when compared with the converted and
ombined trans-septal procedures (groups A and B).
Thus, the direct LV access for these types of cardiac
nterventions may become a preferred route if, indeed, the
rocedural and fluoroscopy times are shorter and the com-
lication rates are acceptable.
Study limitations. This study includes only patients that had
previous cardiac operations, thus the risk of tamponade in
these patients is decreased.
The presented long-term follow-up is based on clinical or
Figure 7. Average Fluoroscopy Time for Mitral Paravalvular Leaks Closure
Comparison between primary intended transapical approach versus our
own global experience.phone call follow-up. The CTA was not obtained in allpatients at late follow-up, and therefore, we cannot exclude
late LV pseudoaneurysm formation at the site of puncture
site closure.
Conclusions
With meticulous planning, transapical puncture is safe. The
transapical access provides a direct approach to the LV
targets for certain interventional procedures and leads to a
significant decrease of the procedural and fluoroscopy times.
Device closure of the direct LV access site is a reliable and
safe method of hemostasis. Placement of a closure device
should be considered if sheaths larger than 5-F are used.
Although we used this technique only for paravalvular leak
and LV pseudoaneurysm closure, it may have application for
other percutaneous structural heart interventions.
Reprint requests and correspondence: Dr. Carlos E. Ruiz, Lenox
Hill Heart and Vascular Institute of New York, 130 East 77th
Street, 9th Floor Black Hall, New York, New York 10021-10075.
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